###begin article-title 0
A uniform procedure for the purification of CDK7/CycH/MAT1, CDK8/CycC and CDK9/CycT1
###end article-title 0
###begin p 1
###xml 165 166 165 166 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 269 290 269 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Spodoptera frugiperda</italic>
###xml 354 356 354 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 616 621 616 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 269 290 <span type="species:ncbi:7108">Spodoptera frugiperda</span>
We have established a uniform procedure for the expression and purification of the cyclin-dependent kinases CDK7/CycH/MAT1, CDK8/CycC and CDK9/CycT1. We attach a His6-tag to one of the subunits of each complex and then co-express it together with the other subunits in Spodoptera frugiperda insect cells. The CDK complexes are subsequently purified by Ni2+-NTA and Mono S chromatography. This approach generates large amounts of active recombinant kinases that are devoid of contaminating kinase activities. Importantly, the properties of these recombinant kinases are similar to their natural counterparts (Pinhero et al. 2004, Eur J Biochem 271:1004-14). Our protocol provides a novel systematic approach for the purification of these three (and possibly other) recombinant CDKs.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B1" ref-type="bibr">1</xref>
Cyclin-dependent kinases (CDKs) play important roles in the regulation of eukaryotic cell cycle and gene expression. They represent a family of Ser/Thr protein kinases that are critically dependent on their association with a cyclin partner (1). In addition, these kinases are regulated by a variety of mechanisms including phosphorylation events, association with inhibitory proteins and assembly factors, and protein degradation (1).
###end p 3
###begin p 4
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">3</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B3" ref-type="bibr">3</xref>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">4</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 490 491 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 780 781 780 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 937 938 937 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
###xml 1027 1028 1027 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B6" ref-type="bibr">6</xref>
###xml 1113 1114 1113 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B7" ref-type="bibr">7</xref>
###xml 1082 1085 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Three CDKs (CDK7, CDK8 and CDK9) have been implicated in the phosphorylation of the carboxyl-terminal domain (CTD) of the largest subunit of RNA polymerase II (RNA pol II) (2, 3). The phosphorylation of this domain is essential for several post-initiation events during the synthesis of mRNA in all eukaryotes (2, 3). It is important that CDK7, CDK8 and CDK9 are biochemically and functionally distinct kinases (4, 5) that execute non-redundant functions during the transcription reaction (2). CDK7 exists in several forms including a core tri-partite CDK7/CycH/MAT1 complex known as CAK (cyclin-dependent kinase activating kinase), as a component in the general transcription factor TFIIH and as a component of larger complexes containing pol II and other transcription factors (2). CDK8/CycC exists as a bipartite complex, but has also been found in a variety of complexes that contain pol II and general pol II transcription factors (2). CDK9 was initially identified as P-TEFb (Positive Transcription Elongation Factor-b) (6). Independently, CDK9/CycT1 has been isolated as the HIV-tat associated kinase TAK (7).
###end p 4
###begin p 5
###xml 119 127 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus </italic>
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B8" ref-type="bibr">8</xref>
###xml 345 346 337 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B9" ref-type="bibr">9</xref>
###xml 348 350 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B10" ref-type="bibr">10</xref>
###xml 382 384 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B11" ref-type="bibr">11</xref>
###xml 413 415 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B12" ref-type="bibr">12</xref>
###xml 447 449 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B13" ref-type="bibr">13</xref>
###xml 119 126 <span type="species:ncbi:8355">Xenopus</span>
CDK7/CycH/MAT1 acts as a cyclin-dependent kinase activating kinase that phosphorylates and activates different CDKs in Xenopus and mammalian extracts (8). As a component of the general transcription factor TFIIH, this complex also phosphorylates the carboxyl-terminal domain of pol II. The retinoic acid receptors (RAR)-alpha-1 and (RAR)-gamma (9, 10), the estrogen receptor-alpha (11), the transactivator Oct-1 (12) and the tumor suppressor p53 (13) have also been identified as substrates of CDK7. The substrate preferences of CDK8/CycC and CDK9/CycT1 have not been extensively characterized.
###end p 5
###begin p 6
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">14</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">14</xref>
All of the previous studies on CDK7, CDK8 and CDK9 were carried out with kinases that were immunoprecipitated from cell extracts or by epitope-tagged recombinant kinases that were purified by analytical scale affinity schemes (for references see (14)). In many cases, the homogeneity of the preparations and the presence of contaminating kinase activities were not systematically addressed. In order to circumvent these problems and the variance that could result from the differences in the purification strategies, we designed a uniform procedure for the purification of recombinant CDK7, CDK8 and CDK9 complexes. Using these recombinant kinases, we identified additional differences in the preference of these kinases towards different parts of the pol II CTD (14). In this manuscript, we provide extensive details on the expression/purification protocols for the three recombinant kinases that will be of use in future attempts to prepare these as well as other cyclin-dependent kinases.
###end p 6
###begin title 7
Materials and Methods
###end title 7
###begin title 8
###xml 0 18 0 18 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression vectors</bold>
Expression vectors
###end title 8
###begin title 9
###xml 40 41 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 0 46 0 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a. Baculovirus for the expression of His<sub>6</sub>-CDK8</italic>
a. Baculovirus for the expression of His6-CDK8
###end title 9
###begin p 10
###xml 124 125 124 125 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 723 724 723 724 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 760 781 760 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Spodoptera frugiperda</italic>
###xml 136 141 <span type="species:ncbi:9606">human</span>
###xml 760 781 <span type="species:ncbi:7108">Spodoptera frugiperda</span>
###xml 783 786 <span type="species:ncbi:7108">Sf9</span>
The GibcoBRL Bac-to-Bac baculovirus expression system was used to generate recombinant baculovirus for the expression of His6-CDK8. The human CDK8 coding sequence was PCR amplified from pBSCDK8 (a gift from E. Lees) using primers for the T7 promoter and the C-terminus of CDK8 (5'-GCC GAA TTC GAC TAT GAC TTT AAA GTG AAG CTG AGC-3') and sub-cloned into the donor plasmid pFastBacHTa (Invitrogen). To generate the desired recombinant baculovirus, the donor plasmid (pFastBacHTa/CDK8) was transformed into DH10BAC cells, which contain the bacmid (Bmon14272, Invitrogen). Recombinant bacmids were isolated from the blue colonies and the presence of the coding sequence of CDK8 was confirmed by PCR. A bacmid containing the His6-CDK8 sequence was transfected into Spodoptera frugiperda (Sf9) cells using cellfectin. The baculoviruses were amplified and used for protein expression.
###end p 10
###begin title 11
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 0 41 0 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b. Baculovirus expressing His<sub>6</sub>-CDK9/CycT1</italic>
b. Baculovirus expressing His6-CDK9/CycT1
###end title 11
###begin p 12
###xml 49 50 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AcNPV </italic>
###xml 294 295 294 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B15" ref-type="bibr">15</xref>
###xml 404 407 <span type="species:ncbi:7108">Sf9</span>
Recombinant baculovirus for the expression of His6-CDK9/CycT1 was produced using the Novagen Baculovirus expression system. This system utilizes a Bacvector-3000 (Novagen) triple cut virus DNA, which is a modified form of the AcNPV genome. A transfer plasmid cassettes for the expression of His6-CDK9 and CycT1 (pBAC-CDK9/CycT1, a gift from D. Price (15)) and Bacvector-3000 DNA were co-transfected into Sf9 cells. The recombinant baculovirus was amplified and used for protein expression.
###end p 12
###begin title 13
###xml 29 30 29 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 0 35 0 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c. Baculovirus expressing His<sub>6</sub>-CycH</italic>
c. Baculovirus expressing His6-CycH
###end title 13
###begin p 14
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B16" ref-type="bibr">16</xref>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 222 225 <span type="species:ncbi:7108">Sf9</span>
The coding sequence of human CycH (from pBS/CycH, a gift from D. Morgan) was subcloned into pBlueBac2 (Invitrogen). The plasmid and the transfection module B825-03 (digested AcNPV DNA, Invitrogen) were co-transfected into Sf9 cells. Purification of blue plaques (containing recombinant virus) was conducted as in reference (16). The presence of the CycH encoding sequence was confirmed by Northern blot.
###end p 14
###begin p 15
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B17" ref-type="bibr">17</xref>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 124 129 <span type="species:ncbi:9606">human</span>
The baculoviruses for the expression of CDK7 and MAT1 were gifts from D. Morgan (17). The baculovirus for the expression of human CycC was provided by Dr. E. Lees (5).
###end p 15
###begin title 16
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Growth and maintenance of Sf9 cells</bold>
###xml 26 29 <span type="species:ncbi:7108">Sf9</span>
Growth and maintenance of Sf9 cells
###end title 16
###begin p 17
###xml 70 71 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 0 3 <span type="species:ncbi:7108">Sf9</span>
###xml 221 227 <span type="species:ncbi:9913">bovine</span>
Sf9 cells were cultured at 28degreesC in tissue culture flasks (175 cm2, SARSTEDT) in Grace's Medium/1X yeastolate solution/1X lactalbumin hydrolysate solution/1X antibiotic/antimycotic solution (GibcoBRL), and 10% fetal bovine serum (Cansera).
###end p 17
###begin title 18
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Amplification of recombinant viruses</bold>
Amplification of recombinant viruses
###end title 18
###begin p 19
###xml 193 194 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 533 534 533 534 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 758 759 752 753 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 159 162 <span type="species:ncbi:7108">Sf9</span>
###xml 502 505 <span type="species:ncbi:7108">Sf9</span>
High titer viral stocks for the production of recombinant proteins were prepared from low passage (1 or 2) viral stocks by a two-step amplification procedure. Sf9 cells at density of 0.1-0.3x106 cells/ml were infected with individual viruses at a multiplicity of infection (MOI) of 0.1-1. The infected cells were incubated for 5-6 days. The efficiency of infection was monitored by the loss of adherence and the larger size of the cells. The supernatant from these cultures was used to infect a larger Sf9 culture of density 0.5-1x106 cells/ml at a MOI of 1. The culture was incubated for 4-5 days, cells were spun and the supernatant was immediately used or stored at -80degreesC for up to six months. This procedure typically produced viral stocks of ~1x108 pfu/ml.
###end p 19
###begin title 20
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of recombinant kinases</bold>
Expression of recombinant kinases
###end title 20
###begin p 21
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9</sup>
###xml 105 106 105 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 937 939 915 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 86 89 <span type="species:ncbi:7108">Sf9</span>
Expression of recombinant CDK complexes was conducted by co-infecting about 1.5-2x109 Sf9 cells (1.5-2x106 cells/ml) with the appropriate combination of baculoviruses at MOI 4 for each individual virus. The cells were harvested after 48 hours by spinning at 275 g for 5 minutes at 4degreesC, washed with PBS and frozen (-80degreesC) in 15 ml of lysis buffer (10 mM Tris.HCl pH 7.5, 10 mM NaCl, 2 mM b-mercaptoethanol, 0.5 mM EDTA, 10 mM 2-glycerophosphate, 0.5 mM Na-vanadate, 2 mM NaF, 2 mug/ml leupeptin, 2 mug/ml aprotonin, 2 mug/ml pepstatin, 0.2 % (v/v) NP-40, 50 mug/ml PMSF). Alternatively, the cells were immediately lysed in lysis buffer by 10 strokes with a Dounce homogenizer. After cell lysis, the proteins were extracted by adding 0.5M NaCl and 5 mM imidazole, and rocking for 30 min at 4degreesC. The extract was clarified by spinning in a SW50.1 rotor (Beckman) at 75000 g for 30 min and immediately processed by metal (Ni2+) affinity chromatography.
###end p 21
###begin title 22
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 24 0 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ni<sup>2+</sup>-NTA pull-down assay</bold>
Ni2+-NTA pull-down assay
###end title 22
###begin p 23
###xml 101 103 99 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 57 60 <span type="species:ncbi:7108">Sf9</span>
Pull down assays were performed with 250 mul aliquots of Sf9 cell extracts and 50 mul of 50% (v/v) Ni2+-NTA agarose beads equilibrated with 10 mM Tris.HCl, pH 7.6, 0.5 M NaCl, 5 mM imidazole, 50 mug/ml PMSF and 10% (v/v) glycerol (buffer A). The suspension was rocked on a nutator for 1 h and the beads were pelleted by spinning for 1 minute at 3000 rpm. The beads were then washed five times with 1ml of buffer A + 0.1M NaCl, boiled for 5 minutes in SDS-sample buffer and further analyzed by Western blot or silver staining.
###end p 23
###begin title 24
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Purification of CDK complexes by Ni<sup>2+</sup>-NTA chromatography</bold>
Purification of CDK complexes by Ni2+-NTA chromatography
###end title 24
###begin p 25
###xml 78 80 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
The cell extract from about 1 liter of infected cells was mixed with 1ml of Ni2+-NTA agarose beads (Qiagen) that were equilibrated with 10 mM Tris.HCl pH 7.6, 0.5 M NaCl, 5 mM imidazole, 50 mug/ml PMSF and 10% (v/v) glycerol, and rocked on a nutator for 1 h. The beads were washed once in the equilibration buffer and transferred to a disposable 10 ml column (Amersham). Bound proteins were step-wise eluted with 15, 25, 100 and 400 mM imidazole in 10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF and 10% (v/v) glycerol. The fractions containing the recombinant protein kinases were identified by SDS-PAGE/Coomassie Brilliant Blue R-250 staining, pooled and stored at -80degreesC.
###end p 25
###begin title 26
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Purification of CDK complexes by Mono S chromatography</bold>
Purification of CDK complexes by Mono S chromatography
###end title 26
###begin p 27
###xml 36 38 36 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
The pooled protein fractions from Ni2+-NTA chromatography were buffer exchanged in PD10 columns (Amersham) to 25 mM HEPES pH 7.6, 0.1 mM EDTA, 1 mM DTT, 5% (v/v) glycerol, 50 mug/ml PMSF and 80 mM NaCl. The proteins were loaded on a tandem of two 5 ml Econo-Pac Mono S cartridges (BioRad) and eluted with a linear 0.08-0.5M NaCl gradient in 25mM HEPES pH 7.6, 0.1 mM EDTA, 1 mM DTT, 50 mug/ml PMSF, and 5% (v/v) glycerol. The fractions containing recombinant protein kinases were identified by SDS-PAGE/silver staining and stored at -80degreesC.
###end p 27
###begin title 28
###xml 0 17 0 17 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kinase substrates</bold>
Kinase substrates
###end title 28
###begin p 29
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 155 161 <span type="species:ncbi:9913">bovine</span>
Glutathione-S-transferase carboxyl terminal domain (GST-CTD) was expressed and purified as described (18). Highly purified myelin basic protein (MBP) from bovine brain was a gift from Dr. G. Harauz.
###end p 29
###begin title 30
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Kinase assays</bold>
Kinase assays
###end title 30
###begin p 31
###xml 108 109 107 108 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 187 188 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 199 201 190 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 1001 1005 985 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1-52</italic>
###xml 1093 1095 1077 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B19" ref-type="bibr">19</xref>
The kinase assays were performed in a volume of 20 mul containing 20 mM Tris.HCl, pH 8, 50 mM KCl, 7 mM MgCl2, 5 mM 2-glycerophosphate, 100 mug/ml BSA (2mug), 10 muM ATP, 2 muCi (7.4 x 104 Bq) alpha-32P-ATP (ICN), 40mug/ml (800 ng) GST-CTD or MBP and about 100-400 ng/ml (2-8 ng) of purified kinase. These amounts correspond to 100-500 fold molar excess of substrate versus kinase. It is important to note that the GST-CTD molecule has at least 52 sites of phosphorylation (52 repeats with a consensus YSPTSPS) on a single molecule, thus additionally increasing the kinase/substrate ratio. MBP also contains multiple sites of phosphorylation. Under the described conditions the kinase reactions are linear for at least three hours (data not shown). The kinase reactions were incubated for 30 minutes at 30degreesC and terminated by the addition of SDS-PAGE loading buffer and then boiled for 5 minutes. Aliquots were analyzed by SDS-PAGE gels and autoradiography. The incorporation of ATP in GST-CTD (1-52) and MBP (pmol of ATP/min/mg of protein) was determined according to the procedure in (19). Kinase assays were also performed in the presence of kinase inhibitors, DRB (5,6-dichlorobenzimidazole riboside), and roscovitine (2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine). DRB was dissolved at 50 mM in 95% ethanol and stored at -20degreesC. Working dilutions of 800, 200 and 40 muM in water were prepared at the time of assay and immediately added to the kinase reaction. Roscovitine was dissolved in DMSO at 50 mM and stored at -20degreesC. Dilutions in water were made prior to the reactions and immediately added to the kinase reaction.
###end p 31
###begin title 32
Results and Discussion
###end title 32
###begin title 33
###xml 0 38 0 38 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Expression of recombinant CDK kinases </bold>
Expression of recombinant CDK kinases 
###end title 33
###begin p 34
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 106 109 <span type="species:ncbi:7108">Sf9</span>
We produced recombinant CDK7/His6-CycH/MAT1, His6-CDK8/CycC and His6-CDK9/CycT1 complexes by co-infecting Sf9 cells with the appropriate combination of baculoviruses. Each virus was applied at MOI of 4. Preliminary experiments have shown that this MOI generates the highest level of expression for all the CDKs and that further increase in MOI did not yield more protein. The expression of the different subunits of the CDK complexes was verified by Western blot with antibodies against CDK7, CycH, MAT1, CDK8, CycC and CDK9. These westerns were not quantitative and do not necessarily mean that all peptides were expressed at similar levels.
###end p 34
###begin p 35
###xml 77 78 77 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 241 242 241 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 10 13 <span type="species:ncbi:7108">Sf9</span>
###xml 390 393 <span type="species:ncbi:7108">Sf9</span>
Monolayer Sf9 cells in large T-flasks were infected at high density (1.5-2x106 cells/ml). We found that this high cell density did not lead to poorer expression or protein degradation as compared to infection at lower cell density (0.5-1 x106 cells/ml). Considering the high cost of growth medium, this approach is more economical. We have not tested if the same trend applies to infecting Sf9 cells that are maintained in suspension.
###end p 35
###begin p 36
###xml 166 174 166 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 209 216 209 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 260 261 260 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">4</xref>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B22" ref-type="bibr">22</xref>
###xml 534 541 534 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 789 797 789 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 863 871 863 871 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 942 949 942 949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 1018 1020 1018 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 1022 1024 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
An important consideration derived from the Western blot analyses was the choice of individual expression of the CDKs and cyclins and their subsequent reconstitution in vitro versus co-expression and assembly in vivo. Both approaches were applied in the past (4, 5, 18, 20-22). Although the Westerns blot analyses were not quantitative, we noticed that a higher level of expression of individual peptides was achieved by co-infection as compared to infection with individual viruses. These observations suggest that complex formation in vivo stabilizes the individual peptides and increases the yields of recombinant proteins. Therefore, we recommend that the production of these kinase complexes is carried out by co-infection rather than individual expression and mixing of the extracts in vitro. It is also important to mention that the mixing of the extracts in vitro poses the risk of inadequate modifications of the individual peptides in vivo that might lead to altered properties of the reconstituted kinases (18, 20).
###end p 36
###begin title 37
###xml 39 41 39 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Confirmation of complex formation by Ni<sup>2+</sup>-NTA pull-down assay</bold>
Confirmation of complex formation by Ni2+-NTA pull-down assay
###end title 37
###begin p 38
###xml 78 80 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 139 141 139 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">1</xref>
###xml 246 247 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 282 283 282 283 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 312 313 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">1</xref>
We confirmed the formation of complexes between the recombinant proteins by Ni2+-NTA pull-down assay. Cell extracts were incubated with Ni 2+-NTA beads and the retained proteins were analyzed by Western blot (Fig. 1A). The results showed that His6-CycH pulls down CDK7 and MAT1, His6-CDK8 pulls down CycC and His6-CDK9 pulls down CycT1 (Fig. 1A).
###end p 38
###begin title 39
###xml 44 47 <span type="species:ncbi:7108">Sf9</span>
Expression and assembly of CDK complexes in Sf9 cells.
###end title 39
###begin p 40
###xml 49 52 <span type="species:ncbi:7108">Sf9</span>
 A: Pull down assays were performed with 250 mul Sf9 cell lysates and 25 mul Ni2+-NTA agarose beads. The proteins were separated on 10% SDS gels, transferred to PVDF membrane and detected by Western blot with antibodies against the polypeptides shown on the left. B: Proteins from the pull down assay was separated on a 10% gel. Silver stained gel is shown. A prominent band of about 87 kDa most likely corresponds to CycT1, whereas the 43 kDa corresponds to His6-CDK9.
###end p 40
###begin p 41
###xml 140 142 140 142 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 175 176 175 176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">1</xref>
###xml 279 286 279 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F1" ref-type="fig">1</xref>
Antibodies against CycT1 were not available. However, a prominent band of about 87 kDa most likely corresponding to CycT1 was detected in Ni2+-NTA pull-down fractions from His6-CDK9/CycT1 infected cells by silver staining (Fig. 1B). Thus, the recombinant proteins form complexes in vivo. Another important conclusion from the image in Fig. 1B is that the pull-down fractions are unclean and should be used only for confirmation of expression and complex formation, but not for fine analyses.
###end p 41
###begin title 42
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 56 0 56 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Purification of CDK complexes by Ni<sup>2+</sup>-NTA chromatography</bold>
Purification of CDK complexes by Ni2+-NTA chromatography
###end title 42
###begin p 43
###xml 80 82 80 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 150 151 150 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F2" ref-type="fig">2</xref>
All the CDK complexes were uniformly purified by a two-step process involving Ni2+-NTA agarose chromatography followed by Mono S chromatography (Fig. 2).
###end p 43
###begin title 44
A strategy for the purification of CDK complexes.
###end title 44
###begin p 45
###xml 157 159 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1 4 <span type="species:ncbi:7108">Sf9</span>
 Sf9 cells were co-infected with the baculoviruses expressing cyclin dependent kinases and their corresponding cyclin partners. Cell extract was loaded on Ni2+-NTA beads and eluted with stepwise imidazole gradients. Fractions containing the recombinant kinases were pooled, buffer exchanged on PD10 column and loaded on Mono S beads and purified by a linear 0.08-0.5 M NaCl gradient.
###end p 45
###begin p 46
###xml 9 11 9 11 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 40 41 40 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">3</xref>
###xml 138 139 138 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 157 158 157 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">3</xref>
###xml 601 603 601 603 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 796 798 796 798 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
During Ni2+-NTA chromatography, CDK7/His6-CycH/MAT1 complexes were eluted at a low imidazole concentration of 25 mM (Fig. 3A), whereas His6-CDK8/CycC and His6-CDK9/CycT1 were eluted at higher imidazole concentrations of 100 and 400 mM, respectively (Figs. 3B and C). At this stage, the fractions containing different recombinant kinases were contaminated with different sets of peptides that in certain cases contributed to estimated 40% of the total protein. We did not investigate the nature of these proteins. Also, we detected a very significant CTD kinase activity in crude extracts and in the Ni2+-NTA fractions from the uninfected cell extracts, which precludes the quick and reliable detection of the expression of the kinases by kinase assays. This observation also indicates that the Ni2+-NTA fractioned kinases are inappropriate for analysis of their kinase activity or other fine assays. This necessitated further purification by ion exchange chromatography to remove the contaminating proteins.
###end p 46
###begin title 47
###xml 35 37 35 37 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Purification of CDK complexes by Ni2+-NTA agarose chromatography.
###end title 47
###begin p 48
###xml 162 164 162 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 92 95 <span type="species:ncbi:7108">Sf9</span>
 A: CDK7/His6-CycH/MAT1; B: His6-CDK8/CycC; C: His6-CDK9/CycT1; D: Proteins from uninfected Sf9 cells. Coomassie stained gels with different fractions from the Ni2+-NTA agarose chromatography of cell extracts are shown. Molecular weight markers are shown on the left. The bands corresponding to the kinases and the cyclin partners are shown on the right. L, load. The concentration of imidazole in the corresponding fractions is shown on the top of the figure.
###end p 48
###begin title 49
###xml 0 54 0 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Purification of CDK complexes by Mono S chromatography</bold>
Purification of CDK complexes by Mono S chromatography
###end title 49
###begin p 50
###xml 29 31 29 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">4</xref>
All the fractions from the Ni2+-NTA agarose chromatography that contained the CDK complexes of interest were pooled and purified by Mono S chromatography. This additional step produced significantly cleaner CDK complexes (Figs. 4A, B and C).
###end p 50
###begin p 51
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">4</xref>
###xml 297 298 297 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 456 457 456 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">4</xref>
###xml 574 575 574 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 615 616 615 616 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 656 657 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 690 692 690 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 942 944 942 944 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
In the case of CDK7/His6-CycH/MAT1, a peak consisting of two bands with molecular weights of approximately 40 and 36 kDa was eluted at a low salt concentration of around 100 mM NaCl (Fig. 4A, lanes 1-9). Western blot analyses (not shown) indicated that the 40 kDa band is a doublet of CDK7 and His6-CycH, while the 36 kDa corresponds to MAT1. It should be noted that the peak was followed by a trail of the 40 kDa band that appeared to possess the CDK7/His6-CycH doublet but lack the MAT1 band (Fig. 4A, lanes 10-15). Our results suggest that besides the tripartite CDK7/His6-CycH/MAT1 complex, a bipartite CDK7/His6-CycH complex and possibly monomeric His6-CycH were purified during the Ni2+-NTA agarose step. Earlier reports have established that the tripartite and bipartite complexes differ in their substrate specificity (18, 20). Thus, the Mono S purification step is necessary not only to exclude the contaminating peptides from the Ni2+-NTA agarose step, but also to resolve these two complexes.
###end p 51
###begin title 52
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Purification of CDK complexes from pooled Ni2+-NTA fractions by Mono S chromatography.
###end title 52
###begin p 53
 A linear gradient of 80-500 NaCl was applied. The 100-460 mM range of the gradient is shown. A: CDK7/His6-CycH/MAT1; B: His6-CDK8/CycC; C: His6-CDK9/CycT1. Silver stained gels with different fractions are shown. Molecular weight markers are shown on the left. The bands corresponding to the kinases and the cyclin partners are shown on the right. L, load.
###end p 53
###begin p 54
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 21 22 21 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">4</xref>
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">4</xref>
###xml 150 151 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 170 171 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 302 303 302 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">4</xref>
###xml 388 389 388 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">4</xref>
###xml 442 443 442 443 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F4" ref-type="fig">4</xref>
###xml 569 570 569 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 582 583 582 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">3</xref>
His6-CDK8/CycC (Fig. 4B, lanes 12-21) and His6-CDK9/CycT1 (Fig. 4C, lanes 15-23) were eluted at higher salt concentrations from the Mono S column. His6-CDK8, CycC and His6-CDK9 were estimated to be approximately 53, 36 and 43 kDa, respectively by Western blot analyses (data not shown). The peak of His6-CDK8/CycC (Fig. 4B, lanes 12-17) was followed by a trail of fractions containing His6-CDK8 only (Fig. 4B, lanes 19-22). In the case of His6-CDK9/CycT1, the peak containing the complex (Fig. 4C, lanes 19-23) was preceded by fractions that contained predominantly His6-CDK9 (Fig. 3C, lanes 15-18). Again, the profile of peptides in the Mono S chromatography fractions clearly indicates that the affinity chromatography step purifies a mixture of assembled complexes and monomeric tagged polypeptides. This observation should be considered if the properties of the monomeric subunits versus the assembled complex are to be analyzed.
###end p 54
###begin title 55
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Recovery of recombinant CDKs</bold>
Recovery of recombinant CDKs
###end title 55
###begin p 56
###xml 101 103 101 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink">, </bold>
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 153 154 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 243 244 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 302 304 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F3" ref-type="fig">3</xref>
###xml 66 69 <span type="species:ncbi:7108">Sf9</span>
We estimate that, on an average, from 1 liter culture of infected Sf9 cells, we purified about 115 mg, 880 mg and 1.2 mg of pure CDK7/His6-CycH/MAT1, His6-CDK8/CycC and His6-CDK9/CycT1 respectively. We suspect that the lower yield of CDK7/ His6-CycH/MAT1 is stemming from its poorer affinity towards Ni2+-NTA agarose as exemplified by its elution at lower imidazole concentration (Fig. 3A).
###end p 56
###begin title 57
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Activity of the kinases</bold>
Activity of the kinases
###end title 57
###begin title 58
Phosphorylation of GST-CTD and MBP by CDK7/His6-CycH/MAT1, His6-CDK8/CycC and His6-CDK9/CycT1.
###end title 58
###begin p 59
 Lanes 1, 4, and 7 are kinases without any substrate. CDK8 and CDK9 have background bands that resulted from their autophosphorylation. CDK7 produced two bands with GST-CTD, the low mobility band corresponds to the hyperphosphorylated form (IIo), and the higher mobility band, the hypophosphorylated IIa. CDK8 and CDK9 produced only the IIa form.
###end p 59
###begin p 60
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">14</xref>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">5</xref>
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F5" ref-type="fig">5</xref>
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 306 307 306 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 478 479 478 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 747 749 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">14</xref>
###xml 620 623 <span type="species:ncbi:7108">Sf9</span>
The functional activities of the purified kinases were studied using GST-CTD and MBP as substrates ((14) and Fig. 5)). All the kinases phosphorylated GST-CTD and MBP (Fig. 5). CDK7/His6-CycH/MAT1 transferred 1.6 and 0.94 nmols of ATP/min/mg protein with GST-CTD and MBP as substrates, respectively. The His6-CDK8/CycC preparations showed somewhat lower specific activities of 0.1 and 0.15 nmols of ATP/min/mg protein with GST-CTD and MBP, whereas the specific activities for His6-CDK9/CycT1 were 0.38 and 3.74 nmols of ATP/min/mg protein. No kinase activity was detected in the corresponding fractions from non-infected Sf9 cell. Importantly, the purified kinases displayed distinct patterns of CTD phosphorylation, which were reported elsewhere (14).
###end p 60
###begin p 61
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B23" ref-type="bibr">23</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B25" ref-type="bibr">25</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B26" ref-type="bibr">26</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
###xml 379 380 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
###xml 436 437 436 437 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 454 455 454 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
###xml 517 518 517 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
###xml 624 625 624 625 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 642 643 642 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
###xml 755 756 755 756 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 774 775 774 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
###xml 839 840 839 840 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 857 858 857 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
###xml 888 889 888 889 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 945 946 945 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
As reported by others, roscovitine is a potent inhibitor of CDK7 and CDK9, but not CDK8 (23-25), whereas DRB inhibits CDK9 at lower concentrations as compared to CDK7 (26). We used this information and performed several experiments to confirm the catalytical purity of the kinases. In Fig. 6, we show that, in agreement with the literature, roscovitine strongly inhibits CDK7/His6-CycH/MAT1 (Fig. 6, upper panel, lanes 1-5), but not His6-CDK8/CycC (Fig. 6, upper panel, lanes 6-10). In addition, we also show that His6-CDK9/CycT1 (Fig. 6, upper panel, lanes 11-15) is equally sensitive to roscovitine as compared to CDK7/His6-CycH/MAT1 (Fig. 6, upper panel, lanes 1-5, see also the graph in the lower panel of the figure). DRB is a potent inhibitor of His6-CDK9/CycT1 (Fig. 6, lower panel, lanes 11-15) and a moderate inhibitor of CDK7/His6-CycH/MAT1 (Fig. 6, lower panel, lanes 1-5). His6-CDK8/CycC showed intermediate sensitivity to DRB (Fig. 6, lower panel, lanes 6-10). Together, this data shows the expected inhibition patterns of these kinases with two independent kinase inhibitors thus supporting the notion of their catalytic purity.
###end p 61
###begin title 62
Effect of roscovitine and DRB on the phosphorylation of GST-CTD by CDK7/His6-CycH/MAT1, His6-CDK8/CycC and His6-CDK9/CycT1.
###end title 62
###begin p 63
 Roscovitine and DRB were added to the kinase reaction mixtures at concentrations indicated and kinase reactions were carried out as described in Materials and Methods. Lanes 1, 6 and 11 are kinases without substrate. The graph shows the percentage of the kinase activity as compared to their corresponding activity without inhibitors.
###end p 63
###begin title 64
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Significance and novelty of the proposed purification procedure</bold>
Significance and novelty of the proposed purification procedure
###end title 64
###begin p 65
###xml 670 671 670 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
The significance of this uniform procedure is rationalized as follows. When CDK complexes are obtained by different expression/purification methods, there is a real risk for the introduction of contaminating kinases and other peptides. Consequently, the comparison of such complexes can be impaired by the nature of the impurities. This concern is especially valid when working with immunoprecipitated complexes, which may contain other kinases that are difficult to track. If the immunoprecipitates are derived from crude extracts, it is also possible that the experiment will be conducted with multiple forms of these complexes that share the same CDK component (see (2) for reference).
###end p 65
###begin p 66
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">4</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B27" ref-type="bibr">27</xref>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B29" ref-type="bibr">29</xref>
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B4" ref-type="bibr">4</xref>
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B5" ref-type="bibr">5</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B18" ref-type="bibr">18</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B20" ref-type="bibr">20</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B30" ref-type="bibr">30</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">14</xref>
###xml 699 700 699 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B2" ref-type="bibr">2</xref>
Many of the studies that have characterized CDK7, CDK8 and CDK9 have used either immunoprecipitated enzyme complexes (4, 27-29) or different methods for purification of different kinases (4, 5, 18, 20, 30). In order to achieve a high precision in the comparison of the three CDK complexes, we expressed and purified them by a uniform procedure. This procedure generates large amounts of kinases that are practically devoid of other kinase activities. It is important that this procedure enabled us to identify distinct preferences of CDK7, CDK8 and CDK9 towards different parts of pol II CTD (14). This analysis is demanding. The CTD consists of 52 repeats of a Ser/Thr-rich consensus heptapeptide (2) which might attract promiscuous kinase activities. We believe that our success in these analyses demonstrates the high value of the proposed procedure.
###end p 66
###begin p 67
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="F6" ref-type="fig">6</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B14" ref-type="bibr">14</xref>
We did not detect measurable CTD kinase activities in the corresponding fractions from uninfected cells, meaning that our preparations are not contaminated with independent co-purifying CTD kinase activities. At the same time, we observed different patterns of contaminating peptides in the preparations of CDK7, CDK8, and CDK9. Our interpretation is that these peptides co-purified probably because of interactions with the complexes. We are not sure how these peptides contributed to the activity and specificity of each kinase. The inhibitory studies with roscovitine and DRB (see Fig. 6) and juglone (14) suggest that most if not all of the CTD kinase activities should be attributed to the recombinant kinases. However, we can not exclude the possibility that minor amounts of very active contaminating kinases could alter the results with other substrates. We recommend that a set of inhibitory studies is preformed with each substrate to minimize these risks.
###end p 67
###begin p 68
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="B15" ref-type="bibr">15</xref>
###xml 155 156 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
###xml 179 180 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">6</sub>
A similar, but not identical procedure for the purification of His-CDK9/CycT1 was used in an earlier study (15). The procedures for the purification of His6-CDK8/CycC and CDK7/His6-CycH/MAT1 are novel.
###end p 68
###begin p 69
We believe that our systematic approach can be applied effectively to characterize other CDKs. In addition, we believe that the presented details on the purification of the three CDKs can be of use when other finer analyses of CDK7, CDK8 and CDK9 are conducted.
###end p 69
###begin p 70
We thank Drs. D. Morgan, E. Lees and D. Price for providing baculoviruses and vectors for the expression of the recombinant kinases. MBP was a gift from Dr. G. Harauz. This study was supported by grants to K. Y. from the Natural Sciences and Engineering Research Council of Canada (NSERC #217548) and the Ontario Genomics Institute (OGI #043567).
###end p 70
###begin title 71
Abbreviations
###end title 71
###begin p 72
cyclin-dependent kinase
###end p 72
###begin p 73
carboxyl-terminal domain of RNA polymerase II
###end p 73
###begin p 74
cyclin
###end p 74
###begin p 75
myelin basic protein
###end p 75
###begin title 76
References
###end title 76
###begin article-title 77
Cyclin-dependent kinases: engines, clocks, and microprocessors. The dynamics of cyclin dependent kinase structure.
###end article-title 77
###begin article-title 78
Regulation of transcription elongation by phosphorylation.
###end article-title 78
###begin article-title 79
Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation.
###end article-title 79
###begin article-title 80
Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences.
###end article-title 80
###begin article-title 81
Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases.
###end article-title 81
###begin article-title 82
P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II.
###end article-title 82
###begin article-title 83
Tat-associated kinase (P-TEFb): a component of transcription preinitiation and elongation complexes.
###end article-title 83
###begin article-title 84
Cyclin-dependent kinase-7 - at the cross-roads of transcription, DNA-repair and cell-cycle control.
###end article-title 84
###begin article-title 85
Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7.
###end article-title 85
###begin article-title 86
TFIIH interacts with the retinoic acid receptor gamma and phosphorylates its AF-1-activating domain through cdk7.
###end article-title 86
###begin article-title 87
Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7.
###end article-title 87
###begin article-title 88
The cyclin-dependent kinase-activating kinase (CAK) assembly factor, MAT1, targets and enhances CAK activity on the POU domains of octamer transcription factors.
###end article-title 88
###begin article-title 89
p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner.
###end article-title 89
###begin article-title 90
Three cyclin-dependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II.
###end article-title 90
###begin article-title 91
###xml 46 51 <span type="species:ncbi:9606">human</span>
Identification of multiple cyclin subunits of human P-TEFb.
###end article-title 91
###begin article-title 92
Bacterial luciferase produced with rapid-screening baculovirus vectors is a sensitive reporter for infection of insect cells and larvae.
###end article-title 92
###begin article-title 93
Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase.
###end article-title 93
###begin article-title 94
Regulation of CDK7 substrate specificity by MAT1 and TFIIH.
###end article-title 94
###begin article-title 95
###xml 81 84 <span type="species:ncbi:10116">rat</span>
Calcium-activated, phospholipid-dependent protein kinase (protein kinase C) from rat brain.
###end article-title 95
###begin article-title 96
Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH.
###end article-title 96
###begin article-title 97
A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase.
###end article-title 97
###begin article-title 98
T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity.
###end article-title 98
###begin article-title 99
The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382.
###end article-title 99
###begin article-title 100
Cyclin-dependent kinases as cellular targets for antiviral drugs.
###end article-title 100
###begin article-title 101
###xml 74 96 <span type="species:ncbi:10335">varicella-zoster virus</span>
Roscovitine, a cyclin-dependent kinase inhibitor, prevents replication of varicella-zoster virus.
###end article-title 101
###begin article-title 102
Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy.
###end article-title 102
###begin article-title 103
###xml 117 152 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.
###end article-title 103
###begin article-title 104
Heat-shock inactivation of the tfiih-associated kinase and change in the phosphorylation sites on the c-terminal domain of RNA-polymerase-II.
###end article-title 104
###begin article-title 105
###xml 36 41 <span type="species:ncbi:9606">human</span>
Biochemical characterization of the human cyclin-dependent protein kinase activating kinase.
###end article-title 105
###begin article-title 106
Mat1, cdk7 and cyclin-H form a kinase complex which is uv light-sensitive upon association with TFIIH.
###end article-title 106
###begin title 107
Appendix
###end title 107
###begin title 108
Protocols
###end title 108
###begin title 109
###xml 0 35 0 35 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Amplification of baculovirus stocks</bold>
Amplification of baculovirus stocks
###end title 109
###begin p 110
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 0 163 0 163 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="111">Infect 10 ml Sf9 insect culture in a 25 cm<sup>2 </sup>T-flask (SARSTEDT) at a density of 0.1-0.3x10<sup>6</sup> cells/ml with 0.1 ml of virus stock passage 1 or passage 2 (MOI 0.1-1.).</p>
###xml 0 163 0 163 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="111">Infect 10 ml Sf9 insect culture in a 25 cm<sup>2 </sup>T-flask (SARSTEDT) at a density of 0.1-0.3x10<sup>6</sup> cells/ml with 0.1 ml of virus stock passage 1 or passage 2 (MOI 0.1-1.).</p></list-item>
###xml 163 359 163 353 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="112">Incubate the cells for 5-6 days at 28&#176;C. We consider that 100% infection is achieved when all the cells are detached from the substrate. Normally, 100% of the infection is observed by day 4.</p>
###xml 163 359 163 353 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="112">Incubate the cells for 5-6 days at 28&#176;C. We consider that 100% infection is achieved when all the cells are detached from the substrate. Normally, 100% of the infection is observed by day 4.</p></list-item>
###xml 359 439 353 433 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="113">Pellet the cells by spinning at 275xg for 5 minutes and collect the supernatant.</p>
###xml 359 439 353 433 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="113">Pellet the cells by spinning at 275xg for 5 minutes and collect the supernatant.</p></list-item>
###xml 527 528 521 522 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 549 550 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 439 630 433 624 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="114">Use 1 ml of this supernatant to infect a large culture of 75 ml at a density of 0.5-1x10<sup>6</sup> cells/ml in a 175 cm<sup>2</sup> flask (SARSTEDT). Incubate the cells for 4-5 days and collect the supernatant. </p>
###xml 439 630 433 624 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="114">Use 1 ml of this supernatant to infect a large culture of 75 ml at a density of 0.5-1x10<sup>6</sup> cells/ml in a 175 cm<sup>2</sup> flask (SARSTEDT). Incubate the cells for 4-5 days and collect the supernatant. </p></list-item>
###xml 867 869 849 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 630 876 624 858 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="115">Use the supernatant from step 4 for infecting the Sf9 culture for large scale protein expression. The stocks can be stored at 4&#176;C for a week or -80&#176;C for up to six months. These stocks (Passage 4) typically contain about 1x10<sup>8 </sup>pfu/ml.</p>
###xml 630 876 624 858 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="115">Use the supernatant from step 4 for infecting the Sf9 culture for large scale protein expression. The stocks can be stored at 4&#176;C for a week or -80&#176;C for up to six months. These stocks (Passage 4) typically contain about 1x10<sup>8 </sup>pfu/ml.</p></list-item>
###xml 0 876 0 858 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="111">Infect 10 ml Sf9 insect culture in a 25 cm<sup>2 </sup>T-flask (SARSTEDT) at a density of 0.1-0.3x10<sup>6</sup> cells/ml with 0.1 ml of virus stock passage 1 or passage 2 (MOI 0.1-1.).</p></list-item><list-item><p textid="112">Incubate the cells for 5-6 days at 28&#176;C. We consider that 100% infection is achieved when all the cells are detached from the substrate. Normally, 100% of the infection is observed by day 4.</p></list-item><list-item><p textid="113">Pellet the cells by spinning at 275xg for 5 minutes and collect the supernatant.</p></list-item><list-item><p textid="114">Use 1 ml of this supernatant to infect a large culture of 75 ml at a density of 0.5-1x10<sup>6</sup> cells/ml in a 175 cm<sup>2</sup> flask (SARSTEDT). Incubate the cells for 4-5 days and collect the supernatant. </p></list-item><list-item><p textid="115">Use the supernatant from step 4 for infecting the Sf9 culture for large scale protein expression. The stocks can be stored at 4&#176;C for a week or -80&#176;C for up to six months. These stocks (Passage 4) typically contain about 1x10<sup>8 </sup>pfu/ml.</p></list-item></list>
###xml 13 16 <span type="species:ncbi:7108">Sf9</span>
###xml 680 683 <span type="species:ncbi:7108">Sf9</span>
Infect 10 ml Sf9 insect culture in a 25 cm2 T-flask (SARSTEDT) at a density of 0.1-0.3x106 cells/ml with 0.1 ml of virus stock passage 1 or passage 2 (MOI 0.1-1.).Incubate the cells for 5-6 days at 28degreesC. We consider that 100% infection is achieved when all the cells are detached from the substrate. Normally, 100% of the infection is observed by day 4.Pellet the cells by spinning at 275xg for 5 minutes and collect the supernatant.Use 1 ml of this supernatant to infect a large culture of 75 ml at a density of 0.5-1x106 cells/ml in a 175 cm2 flask (SARSTEDT). Incubate the cells for 4-5 days and collect the supernatant. Use the supernatant from step 4 for infecting the Sf9 culture for large scale protein expression. The stocks can be stored at 4degreesC for a week or -80degreesC for up to six months. These stocks (Passage 4) typically contain about 1x108 pfu/ml.
###end p 110
###begin p 111
###xml 42 44 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 89 90 89 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 13 16 <span type="species:ncbi:7108">Sf9</span>
Infect 10 ml Sf9 insect culture in a 25 cm2 T-flask (SARSTEDT) at a density of 0.1-0.3x106 cells/ml with 0.1 ml of virus stock passage 1 or passage 2 (MOI 0.1-1.).
###end p 111
###begin p 112
Incubate the cells for 5-6 days at 28degreesC. We consider that 100% infection is achieved when all the cells are detached from the substrate. Normally, 100% of the infection is observed by day 4.
###end p 112
###begin p 113
Pellet the cells by spinning at 275xg for 5 minutes and collect the supernatant.
###end p 113
###begin p 114
###xml 88 89 88 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Use 1 ml of this supernatant to infect a large culture of 75 ml at a density of 0.5-1x106 cells/ml in a 175 cm2 flask (SARSTEDT). Incubate the cells for 4-5 days and collect the supernatant. 
###end p 114
###begin p 115
###xml 237 239 225 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 50 53 <span type="species:ncbi:7108">Sf9</span>
Use the supernatant from step 4 for infecting the Sf9 culture for large scale protein expression. The stocks can be stored at 4degreesC for a week or -80degreesC for up to six months. These stocks (Passage 4) typically contain about 1x108 pfu/ml.
###end p 115
###begin title 116
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Infecting and harvesting insect cells</bold>
Infecting and harvesting insect cells
###end title 116
###begin p 117
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 73 75 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 0 84 0 84 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="118">Grow Sf9 cells to a density of 1.5-2x10<sup>6</sup> cells/ml in several (5-8) 175 cm<sup>2 </sup>T-flasks.</p>
###xml 0 84 0 84 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="118">Grow Sf9 cells to a density of 1.5-2x10<sup>6</sup> cells/ml in several (5-8) 175 cm<sup>2 </sup>T-flasks.</p></list-item>
###xml 84 331 84 325 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="119">Infect each flask with 2 ml of passage 4 of each of the appropriate viruses and incubate for 48 hours at 28&#176;C. Check the cells for infection under microscope. 100% infection (large floating cells) should be observed 30 hours post infection. </p>
###xml 84 331 84 325 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="119">Infect each flask with 2 ml of passage 4 of each of the appropriate viruses and incubate for 48 hours at 28&#176;C. Check the cells for infection under microscope. 100% infection (large floating cells) should be observed 30 hours post infection. </p></list-item>
###xml 331 413 325 401 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="120">Harvest the cells after 48 hours by spinning at 275x g for 5 minutes at 4&#176;C.</p>
###xml 331 413 325 401 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="120">Harvest the cells after 48 hours by spinning at 275x g for 5 minutes at 4&#176;C.</p></list-item>
###xml 413 539 401 527 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="121">Pour off the supernatant, loosen the pellet by gently shaking it and wash the pellets with 15 ml of phosphate buffered saline.</p>
###xml 413 539 401 527 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="121">Pour off the supernatant, loosen the pellet by gently shaking it and wash the pellets with 15 ml of phosphate buffered saline.</p></list-item>
###xml 539 833 527 808 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="122">Add approximately 3 pellet volumes of Lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 2 mM &#946;-merkaptoethanol, 0.5 mM EDTA, 10 mM 2-glycerophosphate, 0.5 mM Na vanadate, 2 mM NaF, 2 &#956;g/ml leupeptin, 2 &#956;g/ml aprotonin, 2 &#956;g/ml pepstatin, 0.2% NP-40, 50 &#956;g/ml PMSF) and freeze at -80&#176;C.</p>
###xml 539 833 527 808 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="122">Add approximately 3 pellet volumes of Lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 2 mM &#946;-merkaptoethanol, 0.5 mM EDTA, 10 mM 2-glycerophosphate, 0.5 mM Na vanadate, 2 mM NaF, 2 &#956;g/ml leupeptin, 2 &#956;g/ml aprotonin, 2 &#956;g/ml pepstatin, 0.2% NP-40, 50 &#956;g/ml PMSF) and freeze at -80&#176;C.</p></list-item>
###xml 0 833 0 808 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="118">Grow Sf9 cells to a density of 1.5-2x10<sup>6</sup> cells/ml in several (5-8) 175 cm<sup>2 </sup>T-flasks.</p></list-item><list-item><p textid="119">Infect each flask with 2 ml of passage 4 of each of the appropriate viruses and incubate for 48 hours at 28&#176;C. Check the cells for infection under microscope. 100% infection (large floating cells) should be observed 30 hours post infection. </p></list-item><list-item><p textid="120">Harvest the cells after 48 hours by spinning at 275x g for 5 minutes at 4&#176;C.</p></list-item><list-item><p textid="121">Pour off the supernatant, loosen the pellet by gently shaking it and wash the pellets with 15 ml of phosphate buffered saline.</p></list-item><list-item><p textid="122">Add approximately 3 pellet volumes of Lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 2 mM &#946;-merkaptoethanol, 0.5 mM EDTA, 10 mM 2-glycerophosphate, 0.5 mM Na vanadate, 2 mM NaF, 2 &#956;g/ml leupeptin, 2 &#956;g/ml aprotonin, 2 &#956;g/ml pepstatin, 0.2% NP-40, 50 &#956;g/ml PMSF) and freeze at -80&#176;C.</p></list-item></list>
###xml 5 8 <span type="species:ncbi:7108">Sf9</span>
Grow Sf9 cells to a density of 1.5-2x106 cells/ml in several (5-8) 175 cm2 T-flasks.Infect each flask with 2 ml of passage 4 of each of the appropriate viruses and incubate for 48 hours at 28degreesC. Check the cells for infection under microscope. 100% infection (large floating cells) should be observed 30 hours post infection. Harvest the cells after 48 hours by spinning at 275x g for 5 minutes at 4degreesC.Pour off the supernatant, loosen the pellet by gently shaking it and wash the pellets with 15 ml of phosphate buffered saline.Add approximately 3 pellet volumes of Lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 2 mM beta-merkaptoethanol, 0.5 mM EDTA, 10 mM 2-glycerophosphate, 0.5 mM Na vanadate, 2 mM NaF, 2 mug/ml leupeptin, 2 mug/ml aprotonin, 2 mug/ml pepstatin, 0.2% NP-40, 50 mug/ml PMSF) and freeze at -80degreesC.
###end p 117
###begin p 118
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 73 75 73 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 5 8 <span type="species:ncbi:7108">Sf9</span>
Grow Sf9 cells to a density of 1.5-2x106 cells/ml in several (5-8) 175 cm2 T-flasks.
###end p 118
###begin p 119
Infect each flask with 2 ml of passage 4 of each of the appropriate viruses and incubate for 48 hours at 28degreesC. Check the cells for infection under microscope. 100% infection (large floating cells) should be observed 30 hours post infection. 
###end p 119
###begin p 120
Harvest the cells after 48 hours by spinning at 275x g for 5 minutes at 4degreesC.
###end p 120
###begin p 121
Pour off the supernatant, loosen the pellet by gently shaking it and wash the pellets with 15 ml of phosphate buffered saline.
###end p 121
###begin p 122
Add approximately 3 pellet volumes of Lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 2 mM beta-merkaptoethanol, 0.5 mM EDTA, 10 mM 2-glycerophosphate, 0.5 mM Na vanadate, 2 mM NaF, 2 mug/ml leupeptin, 2 mug/ml aprotonin, 2 mug/ml pepstatin, 0.2% NP-40, 50 mug/ml PMSF) and freeze at -80degreesC.
###end p 122
###begin title 123
###xml 0 26 0 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Preparation of cell lysate</bold>
Preparation of cell lysate
###end title 123
###begin p 124
###xml 0 88 0 88 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="125">Thaw the re-suspended cells in an ice bath by gently swirling the tube. Add fresh PMSF. </p>
###xml 0 88 0 88 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="125">Thaw the re-suspended cells in an ice bath by gently swirling the tube. Add fresh PMSF. </p></list-item>
###xml 88 127 88 127 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="126">Leave the lysate on ice for 10 minutes.</p>
###xml 88 127 88 127 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="126">Leave the lysate on ice for 10 minutes.</p></list-item>
###xml 127 222 127 222 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="127">Pass the lysate through a dounce homogenizer 10 times. Check for cell lysis under a microscope.</p>
###xml 127 222 127 222 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="127">Pass the lysate through a dounce homogenizer 10 times. Check for cell lysis under a microscope.</p></list-item>
###xml 222 302 222 302 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="128">Add imidazole and NaCl to a final concentration of 5 mM and 0.5 M, respectively.</p>
###xml 222 302 222 302 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="128">Add imidazole and NaCl to a final concentration of 5 mM and 0.5 M, respectively.</p></list-item>
###xml 302 350 302 350 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="129">Rock the lysate for 30 minutes in the cold room.</p>
###xml 302 350 302 350 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="129">Rock the lysate for 30 minutes in the cold room.</p></list-item>
###xml 350 422 350 416 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="130">Spin at 75000 x g at 4&#176;C in SW50.1 rotor (Beckman) for 30 minutes.</p>
###xml 350 422 350 416 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="130">Spin at 75000 x g at 4&#176;C in SW50.1 rotor (Beckman) for 30 minutes.</p></list-item>
###xml 497 498 491 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 422 554 416 548 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="131">Transfer the supernatant to a fresh pre-chilled tube; add glycerol and MgCl<sub>2</sub> to a final concentration of 10% and 3 mM, respectively.</p>
###xml 422 554 416 548 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="131">Transfer the supernatant to a fresh pre-chilled tube; add glycerol and MgCl<sub>2</sub> to a final concentration of 10% and 3 mM, respectively.</p></list-item>
###xml 0 554 0 548 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="125">Thaw the re-suspended cells in an ice bath by gently swirling the tube. Add fresh PMSF. </p></list-item><list-item><p textid="126">Leave the lysate on ice for 10 minutes.</p></list-item><list-item><p textid="127">Pass the lysate through a dounce homogenizer 10 times. Check for cell lysis under a microscope.</p></list-item><list-item><p textid="128">Add imidazole and NaCl to a final concentration of 5 mM and 0.5 M, respectively.</p></list-item><list-item><p textid="129">Rock the lysate for 30 minutes in the cold room.</p></list-item><list-item><p textid="130">Spin at 75000 x g at 4&#176;C in SW50.1 rotor (Beckman) for 30 minutes.</p></list-item><list-item><p textid="131">Transfer the supernatant to a fresh pre-chilled tube; add glycerol and MgCl<sub>2</sub> to a final concentration of 10% and 3 mM, respectively.</p></list-item></list>
Thaw the re-suspended cells in an ice bath by gently swirling the tube. Add fresh PMSF. Leave the lysate on ice for 10 minutes.Pass the lysate through a dounce homogenizer 10 times. Check for cell lysis under a microscope.Add imidazole and NaCl to a final concentration of 5 mM and 0.5 M, respectively.Rock the lysate for 30 minutes in the cold room.Spin at 75000 x g at 4degreesC in SW50.1 rotor (Beckman) for 30 minutes.Transfer the supernatant to a fresh pre-chilled tube; add glycerol and MgCl2 to a final concentration of 10% and 3 mM, respectively.
###end p 124
###begin p 125
Thaw the re-suspended cells in an ice bath by gently swirling the tube. Add fresh PMSF. 
###end p 125
###begin p 126
Leave the lysate on ice for 10 minutes.
###end p 126
###begin p 127
Pass the lysate through a dounce homogenizer 10 times. Check for cell lysis under a microscope.
###end p 127
###begin p 128
Add imidazole and NaCl to a final concentration of 5 mM and 0.5 M, respectively.
###end p 128
###begin p 129
Rock the lysate for 30 minutes in the cold room.
###end p 129
###begin p 130
Spin at 75000 x g at 4degreesC in SW50.1 rotor (Beckman) for 30 minutes.
###end p 130
###begin p 131
###xml 75 76 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Transfer the supernatant to a fresh pre-chilled tube; add glycerol and MgCl2 to a final concentration of 10% and 3 mM, respectively.
###end p 131
###begin p 132
###xml 75 77 75 77 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Note: You can freeze the sample at this point. If planning to load to the N2+-NTA agarose column on the same day, do not add glycerol.
###end p 132
###begin title 133
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ni<sup>2+</sup>-NTA chromatography</bold>
Ni2+-NTA chromatography
###end title 133
###begin p 134
###xml 19 21 19 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 0 177 0 176 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="135">Equilibrate 1 ml Ni<sup>2+</sup>-NTA agarose beads (Qiagen) with 10 ml of buffer A (10 mM Tris-HCl pH 7.6, 0.5 M NaCl, 5 mM imidazole, 50 &#956;g/ml PMSF, 10% glycerol) in a 50 ml falcon tube.</p>
###xml 0 177 0 176 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="135">Equilibrate 1 ml Ni<sup>2+</sup>-NTA agarose beads (Qiagen) with 10 ml of buffer A (10 mM Tris-HCl pH 7.6, 0.5 M NaCl, 5 mM imidazole, 50 &#956;g/ml PMSF, 10% glycerol) in a 50 ml falcon tube.</p></list-item>
###xml 177 271 176 270 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="136">Spin the beads at 3000 rpm for 2 minutes in a table-top centrifuge and aspire the supernatant.</p>
###xml 177 271 176 270 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="136">Spin the beads at 3000 rpm for 2 minutes in a table-top centrifuge and aspire the supernatant.</p></list-item>
###xml 271 363 270 362 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="137">Add the cell extract from 1 liter of infected cells. Rock the tube for 1 h in the cold room.</p>
###xml 271 363 270 362 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="137">Add the cell extract from 1 liter of infected cells. Rock the tube for 1 h in the cold room.</p></list-item>
###xml 363 586 362 579 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="138">Pellet the beads at 3000 rpm for 2 minutes in a table-top centrifuge, collect the supernatant (flow through) by aspiration, and store at -80&#176;C. If there is any problem with binding, the supernatant can be used again. </p>
###xml 363 586 362 579 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="138">Pellet the beads at 3000 rpm for 2 minutes in a table-top centrifuge, collect the supernatant (flow through) by aspiration, and store at -80&#176;C. If there is any problem with binding, the supernatant can be used again. </p></list-item>
###xml 586 668 579 661 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="139">Add 10 ml buffer A to the beads and transfer to a 15 ml disposable BioRad column. </p>
###xml 586 668 579 661 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="139">Add 10 ml buffer A to the beads and transfer to a 15 ml disposable BioRad column. </p></list-item>
###xml 668 734 661 727 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="140">Wash the column with 10 ml buffer A + 0.1 M NaCl in the cold room.</p>
###xml 668 734 661 727 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="140">Wash the column with 10 ml buffer A + 0.1 M NaCl in the cold room.</p></list-item>
###xml 734 788 727 781 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="141">Elute the proteins as 5 x 1ml fractions in steps using</p>
###xml 734 788 727 781 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="141">Elute the proteins as 5 x 1ml fractions in steps using</p></list-item>
###xml 0 788 0 781 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="135">Equilibrate 1 ml Ni<sup>2+</sup>-NTA agarose beads (Qiagen) with 10 ml of buffer A (10 mM Tris-HCl pH 7.6, 0.5 M NaCl, 5 mM imidazole, 50 &#956;g/ml PMSF, 10% glycerol) in a 50 ml falcon tube.</p></list-item><list-item><p textid="136">Spin the beads at 3000 rpm for 2 minutes in a table-top centrifuge and aspire the supernatant.</p></list-item><list-item><p textid="137">Add the cell extract from 1 liter of infected cells. Rock the tube for 1 h in the cold room.</p></list-item><list-item><p textid="138">Pellet the beads at 3000 rpm for 2 minutes in a table-top centrifuge, collect the supernatant (flow through) by aspiration, and store at -80&#176;C. If there is any problem with binding, the supernatant can be used again. </p></list-item><list-item><p textid="139">Add 10 ml buffer A to the beads and transfer to a 15 ml disposable BioRad column. </p></list-item><list-item><p textid="140">Wash the column with 10 ml buffer A + 0.1 M NaCl in the cold room.</p></list-item><list-item><p textid="141">Elute the proteins as 5 x 1ml fractions in steps using</p></list-item></list>
Equilibrate 1 ml Ni2+-NTA agarose beads (Qiagen) with 10 ml of buffer A (10 mM Tris-HCl pH 7.6, 0.5 M NaCl, 5 mM imidazole, 50 mug/ml PMSF, 10% glycerol) in a 50 ml falcon tube.Spin the beads at 3000 rpm for 2 minutes in a table-top centrifuge and aspire the supernatant.Add the cell extract from 1 liter of infected cells. Rock the tube for 1 h in the cold room.Pellet the beads at 3000 rpm for 2 minutes in a table-top centrifuge, collect the supernatant (flow through) by aspiration, and store at -80degreesC. If there is any problem with binding, the supernatant can be used again. Add 10 ml buffer A to the beads and transfer to a 15 ml disposable BioRad column. Wash the column with 10 ml buffer A + 0.1 M NaCl in the cold room.Elute the proteins as 5 x 1ml fractions in steps using
###end p 134
###begin p 135
###xml 19 21 19 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Equilibrate 1 ml Ni2+-NTA agarose beads (Qiagen) with 10 ml of buffer A (10 mM Tris-HCl pH 7.6, 0.5 M NaCl, 5 mM imidazole, 50 mug/ml PMSF, 10% glycerol) in a 50 ml falcon tube.
###end p 135
###begin p 136
Spin the beads at 3000 rpm for 2 minutes in a table-top centrifuge and aspire the supernatant.
###end p 136
###begin p 137
Add the cell extract from 1 liter of infected cells. Rock the tube for 1 h in the cold room.
###end p 137
###begin p 138
Pellet the beads at 3000 rpm for 2 minutes in a table-top centrifuge, collect the supernatant (flow through) by aspiration, and store at -80degreesC. If there is any problem with binding, the supernatant can be used again. 
###end p 138
###begin p 139
Add 10 ml buffer A to the beads and transfer to a 15 ml disposable BioRad column. 
###end p 139
###begin p 140
Wash the column with 10 ml buffer A + 0.1 M NaCl in the cold room.
###end p 140
###begin p 141
Elute the proteins as 5 x 1ml fractions in steps using
###end p 141
###begin p 142
###xml 0 85 0 84 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="143">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 15 mM imidazole. </p>
###xml 0 85 0 84 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="143">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 15 mM imidazole. </p></list-item>
###xml 85 170 84 168 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="144">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 25 mM imidazole. </p>
###xml 85 170 84 168 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="144">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 25 mM imidazole. </p></list-item>
###xml 170 256 168 253 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="145">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 100 mM imidazole. </p>
###xml 170 256 168 253 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="145">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 100 mM imidazole. </p></list-item>
###xml 256 342 253 338 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="146">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 400 mM imidazole. </p>
###xml 256 342 253 338 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="146">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 400 mM imidazole. </p></list-item>
###xml 0 342 0 338 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="alpha-lower"><list-item><p textid="143">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 15 mM imidazole. </p></list-item><list-item><p textid="144">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 25 mM imidazole. </p></list-item><list-item><p textid="145">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 100 mM imidazole. </p></list-item><list-item><p textid="146">10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 &#956;g/ml PMSF, 10% glycerol and 400 mM imidazole. </p></list-item></list>
10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF, 10% glycerol and 15 mM imidazole. 10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF, 10% glycerol and 25 mM imidazole. 10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF, 10% glycerol and 100 mM imidazole. 10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF, 10% glycerol and 400 mM imidazole. 
###end p 142
###begin p 143
10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF, 10% glycerol and 15 mM imidazole. 
###end p 143
###begin p 144
10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF, 10% glycerol and 25 mM imidazole. 
###end p 144
###begin p 145
10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF, 10% glycerol and 100 mM imidazole. 
###end p 145
###begin p 146
10 mM Tris-HCl pH 7.6, 0.1 M NaCl, 50 mug/ml PMSF, 10% glycerol and 400 mM imidazole. 
###end p 146
###begin p 147
###xml 0 162 0 156 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="148">Run samples of the fractions on SDS-PAGE and stain with Coomassie Brilliant Blue. Pool the fractions containing the proteins of interest and store at -80&#176;C.</p>
###xml 0 162 0 156 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="148">Run samples of the fractions on SDS-PAGE and stain with Coomassie Brilliant Blue. Pool the fractions containing the proteins of interest and store at -80&#176;C.</p></list-item>
###xml 0 162 0 156 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="148">Run samples of the fractions on SDS-PAGE and stain with Coomassie Brilliant Blue. Pool the fractions containing the proteins of interest and store at -80&#176;C.</p></list-item></list>
Run samples of the fractions on SDS-PAGE and stain with Coomassie Brilliant Blue. Pool the fractions containing the proteins of interest and store at -80degreesC.
###end p 147
###begin p 148
Run samples of the fractions on SDS-PAGE and stain with Coomassie Brilliant Blue. Pool the fractions containing the proteins of interest and store at -80degreesC.
###end p 148
###begin title 149
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Mono S chromatography</bold>
Mono S chromatography
###end title 149
###begin p 150
###xml 0 153 0 152 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="151">Equilibrate a PD10 column (Amersham Pharmacia Biotech) with 25 ml of 25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 0.08M NaCl, 1 mM DTT, 50 &#956;g/ml PMSF.</p>
###xml 0 153 0 152 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="151">Equilibrate a PD10 column (Amersham Pharmacia Biotech) with 25 ml of 25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 0.08M NaCl, 1 mM DTT, 50 &#956;g/ml PMSF.</p></list-item>
###xml 201 203 200 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 153 262 152 261 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="152">Buffer exchange the pooled fractions from the Ni<sup>2+</sup>-NTA chromatography step as per manufacturer&#8217;s instruction.</p>
###xml 153 262 152 261 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="152">Buffer exchange the pooled fractions from the Ni<sup>2+</sup>-NTA chromatography step as per manufacturer&#8217;s instruction.</p></list-item>
###xml 262 353 261 352 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="153">Attach two 5 ml Econo-Pac Mono S cartridges (BioRad) in tandem and equilibrate as follows: </p>
###xml 262 353 261 352 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="153">Attach two 5 ml Econo-Pac Mono S cartridges (BioRad) in tandem and equilibrate as follows: </p></list-item>
###xml 0 353 0 352 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="151">Equilibrate a PD10 column (Amersham Pharmacia Biotech) with 25 ml of 25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 0.08M NaCl, 1 mM DTT, 50 &#956;g/ml PMSF.</p></list-item><list-item><p textid="152">Buffer exchange the pooled fractions from the Ni<sup>2+</sup>-NTA chromatography step as per manufacturer&#8217;s instruction.</p></list-item><list-item><p textid="153">Attach two 5 ml Econo-Pac Mono S cartridges (BioRad) in tandem and equilibrate as follows: </p></list-item></list>
Equilibrate a PD10 column (Amersham Pharmacia Biotech) with 25 ml of 25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 0.08M NaCl, 1 mM DTT, 50 mug/ml PMSF.Buffer exchange the pooled fractions from the Ni2+-NTA chromatography step as per manufacturer's instruction.Attach two 5 ml Econo-Pac Mono S cartridges (BioRad) in tandem and equilibrate as follows: 
###end p 150
###begin p 151
Equilibrate a PD10 column (Amersham Pharmacia Biotech) with 25 ml of 25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 0.08M NaCl, 1 mM DTT, 50 mug/ml PMSF.
###end p 151
###begin p 152
###xml 48 50 48 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Buffer exchange the pooled fractions from the Ni2+-NTA chromatography step as per manufacturer's instruction.
###end p 152
###begin p 153
Attach two 5 ml Econo-Pac Mono S cartridges (BioRad) in tandem and equilibrate as follows: 
###end p 153
###begin p 154
###xml 0 105 0 104 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="155">5 ml of buffer A (25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, 50 &#956;g/ml PMSF) at 0.5 ml/min.</p>
###xml 0 105 0 104 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="155">5 ml of buffer A (25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, 50 &#956;g/ml PMSF) at 0.5 ml/min.</p></list-item>
###xml 105 133 104 132 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="156">5 ml of buffer A at 1ml/min.</p>
###xml 105 133 104 132 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="156">5 ml of buffer A at 1ml/min.</p></list-item>
###xml 133 162 132 161 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="157">10 ml of 1M NaCl in buffer A.</p>
###xml 133 162 132 161 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="157">10 ml of 1M NaCl in buffer A.</p></list-item>
###xml 162 219 161 218 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="158">5 ml of gradient 1M - 80 mM NaCl in buffer A at 1 ml/min.</p>
###xml 162 219 161 218 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="158">5 ml of gradient 1M - 80 mM NaCl in buffer A at 1 ml/min.</p></list-item>
###xml 219 252 218 251 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="159">15 ml of 80 mM NaCl in buffer A. </p>
###xml 219 252 218 251 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="159">15 ml of 80 mM NaCl in buffer A. </p></list-item>
###xml 0 252 0 251 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="alpha-lower"><list-item><p textid="155">5 ml of buffer A (25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, 50 &#956;g/ml PMSF) at 0.5 ml/min.</p></list-item><list-item><p textid="156">5 ml of buffer A at 1ml/min.</p></list-item><list-item><p textid="157">10 ml of 1M NaCl in buffer A.</p></list-item><list-item><p textid="158">5 ml of gradient 1M - 80 mM NaCl in buffer A at 1 ml/min.</p></list-item><list-item><p textid="159">15 ml of 80 mM NaCl in buffer A. </p></list-item></list>
5 ml of buffer A (25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, 50 mug/ml PMSF) at 0.5 ml/min.5 ml of buffer A at 1ml/min.10 ml of 1M NaCl in buffer A.5 ml of gradient 1M - 80 mM NaCl in buffer A at 1 ml/min.15 ml of 80 mM NaCl in buffer A. 
###end p 154
###begin p 155
5 ml of buffer A (25 mM HEPES, pH 7.6, 5% glycerol, 0.1 mM EDTA, 1 mM DTT, 50 mug/ml PMSF) at 0.5 ml/min.
###end p 155
###begin p 156
5 ml of buffer A at 1ml/min.
###end p 156
###begin p 157
10 ml of 1M NaCl in buffer A.
###end p 157
###begin p 158
5 ml of gradient 1M - 80 mM NaCl in buffer A at 1 ml/min.
###end p 158
###begin p 159
15 ml of 80 mM NaCl in buffer A. 
###end p 159
###begin p 160
###xml 0 65 0 65 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="161">Load the column at 1ml/min and collect the flow through and save.</p>
###xml 0 65 0 65 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="161">Load the column at 1ml/min and collect the flow through and save.</p></list-item>
###xml 65 129 65 129 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="162">Wash the column with 5 ml of 80 mM NaCl in buffer A at 1 ml/min.</p>
###xml 65 129 65 129 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="162">Wash the column with 5 ml of 80 mM NaCl in buffer A at 1 ml/min.</p></list-item>
###xml 129 209 129 209 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="163">Elute with a linear gradient of 20 ml of 80-500 mM NaCl in buffer A at 1 ml/min.</p>
###xml 129 209 129 209 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="163">Elute with a linear gradient of 20 ml of 80-500 mM NaCl in buffer A at 1 ml/min.</p></list-item>
###xml 209 283 209 282 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="164">Collect 1 ml fractions in 1.5 ml tubes containing 100 &#956;l of 80% glycerol.</p>
###xml 209 283 209 282 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="164">Collect 1 ml fractions in 1.5 ml tubes containing 100 &#956;l of 80% glycerol.</p></list-item>
###xml 283 409 282 402 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="165">Analyze the samples of the fractions by SDS-PAGE and silver staining. Pool the fractions of interest and store at -80&#176;C.</p>
###xml 283 409 282 402 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="165">Analyze the samples of the fractions by SDS-PAGE and silver staining. Pool the fractions of interest and store at -80&#176;C.</p></list-item>
###xml 0 409 0 402 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="161">Load the column at 1ml/min and collect the flow through and save.</p></list-item><list-item><p textid="162">Wash the column with 5 ml of 80 mM NaCl in buffer A at 1 ml/min.</p></list-item><list-item><p textid="163">Elute with a linear gradient of 20 ml of 80-500 mM NaCl in buffer A at 1 ml/min.</p></list-item><list-item><p textid="164">Collect 1 ml fractions in 1.5 ml tubes containing 100 &#956;l of 80% glycerol.</p></list-item><list-item><p textid="165">Analyze the samples of the fractions by SDS-PAGE and silver staining. Pool the fractions of interest and store at -80&#176;C.</p></list-item></list>
Load the column at 1ml/min and collect the flow through and save.Wash the column with 5 ml of 80 mM NaCl in buffer A at 1 ml/min.Elute with a linear gradient of 20 ml of 80-500 mM NaCl in buffer A at 1 ml/min.Collect 1 ml fractions in 1.5 ml tubes containing 100 mul of 80% glycerol.Analyze the samples of the fractions by SDS-PAGE and silver staining. Pool the fractions of interest and store at -80degreesC.
###end p 160
###begin p 161
Load the column at 1ml/min and collect the flow through and save.
###end p 161
###begin p 162
Wash the column with 5 ml of 80 mM NaCl in buffer A at 1 ml/min.
###end p 162
###begin p 163
Elute with a linear gradient of 20 ml of 80-500 mM NaCl in buffer A at 1 ml/min.
###end p 163
###begin p 164
Collect 1 ml fractions in 1.5 ml tubes containing 100 mul of 80% glycerol.
###end p 164
###begin p 165
Analyze the samples of the fractions by SDS-PAGE and silver staining. Pool the fractions of interest and store at -80degreesC.
###end p 165
###begin title 166
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Equipment</bold>
Equipment
###end title 166
###begin p 167
###xml 0 19 0 19 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="168">Tissue culture hood</p>
###xml 0 19 0 19 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="168">Tissue culture hood</p></list-item>
###xml 19 70 19 70 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="169">Basic radiation safety equipment and Geiger counter</p>
###xml 19 70 19 70 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="169">Basic radiation safety equipment and Geiger counter</p></list-item>
###xml 70 107 70 107 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="170">Ultracentrifuge, centrifuge (Beckman)</p>
###xml 70 107 70 107 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="170">Ultracentrifuge, centrifuge (Beckman)</p></list-item>
###xml 107 152 107 152 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="171">Mini-PROTEAN II electrophoresis cell (BioRad)</p>
###xml 107 152 107 152 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="171">Mini-PROTEAN II electrophoresis cell (BioRad)</p></list-item>
###xml 152 228 152 228 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="172">Microcentrifuge, incubator, standard Molecular Biology equipments, gel dryer</p>
###xml 152 228 152 228 <list-item xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="172">Microcentrifuge, incubator, standard Molecular Biology equipments, gel dryer</p></list-item>
###xml 0 228 0 228 <list xmlns:xlink="http://www.w3.org/1999/xlink" list-type="order"><list-item><p textid="168">Tissue culture hood</p></list-item><list-item><p textid="169">Basic radiation safety equipment and Geiger counter</p></list-item><list-item><p textid="170">Ultracentrifuge, centrifuge (Beckman)</p></list-item><list-item><p textid="171">Mini-PROTEAN II electrophoresis cell (BioRad)</p></list-item><list-item><p textid="172">Microcentrifuge, incubator, standard Molecular Biology equipments, gel dryer</p></list-item></list>
Tissue culture hoodBasic radiation safety equipment and Geiger counterUltracentrifuge, centrifuge (Beckman)Mini-PROTEAN II electrophoresis cell (BioRad)Microcentrifuge, incubator, standard Molecular Biology equipments, gel dryer
###end p 167
###begin p 168
Tissue culture hood
###end p 168
###begin p 169
Basic radiation safety equipment and Geiger counter
###end p 169
###begin p 170
Ultracentrifuge, centrifuge (Beckman)
###end p 170
###begin p 171
Mini-PROTEAN II electrophoresis cell (BioRad)
###end p 171
###begin p 172
Microcentrifuge, incubator, standard Molecular Biology equipments, gel dryer
###end p 172

